Centurion Labs Recalls Ninjacof and Ninjacof A

News
Article

The company is voluntarily recalling the products because of potential contamination with Burkholderia cepacia.

On August 22, 2017, Centurion Labs announced it was voluntarily recalling one lot of Ninjacof and one lot of Ninjacof A to the retail level because of the potential for Burkholderia cepacia (B. cepacia) contamination. The recall is a precautionary measure taken after the company was notified by FDA that the product may have been manufactured in a facility that had product contaminated by B. cepacia.

Ninjacof and Ninjacof A are used to treat symptoms of the common cold, allergic rhinitis, or other respiratory allergies. Patients with compromised immune systems or chronic lung conditions who use product contaminated by B. cepacia could develop infections, according to the company. As of the August 22, Centurion Labs has not found B. cepacia in product nor has it received any customer complaints. 

The affected product was manufactured by Vilvet (Dania Beach, FL) and distributed by Centurion Labs. The recalled lots, Ninjacof Lot# 200N1601 (NDC 23359-032-16) and Ninjacof A with Lot# 201NA1601 (NDC 23359-033-16), were distributed in Alabama, Arkansas, Florida, Georgia, Louisiana, Missouri, Mississippi, New Jersey, North Carolina, Ohio, Oklahoma, South Carolina, Tennessee, and Texas.

The company is recommending that patients, pharmacies, and healthcare facilities stop use of the product immediately. Adverse events can be reported to FDA via its website

Source: FDA

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.